The SeroCoV study is a household-based cross-sectional study that aims to estimate the prevalence of anti-SARS-CoV-2 IgG antibodies and associated risk factors in three African countries: Burkina Faso, Ghana, and Madagascar. Commmunity members from altogether 5 urban sites that are 10 years or older are recruited using using a two-stage cluster sampling approach. The primary outcome measure is the proportion of the population that has been exposed to the virus and have developed anti SARS-CoV-2 antibodies; measured by Enzyme-linked Immunosorbent Assays (ELISAs).

Teams at partner institutions:

Team Hamburg: Eva Lorenz, Christina Deschermeier, Ben Rushton, Jenny Kettenbeil, Wibke Loag.            

Team Burkina Faso: Aurélia Souares, Ali Sié, Thierry Ouedraogo, Valentin Buodo.                                   

Team Ghana: John Amuasi, Anthony Afum-Adjei Awuah, Christian Obirikorang.                                      

Team Madagascar: Daniela Fusco, Rivo Rakotoarivelo, Dominik Benke, Yannick Hoeppner